Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Efficacy of the Combination of Simvastatin Plus Rifaximin in Patients With Decompensated Cirrhosis to Prevent ACLF Development: a Multicenter, Double-blind, Placebo Controlled Randomized Clinical Trial

NCT03780673 is registered in ClinicalTrials.gov with Judit Pich as lead sponsor.

NCT NCT03780673
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03780673 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Efficacy of the Combination of Simvastatin Plus Rifaximin in Patients With Decompensated Cirrhosis to Prevent ACLF Development: a Multicenter, Double-blind, Placebo Controlled Randomized Clinical Trial
Lead sponsor
Judit Pich
Phase
Phase 2/3
Overall status
Completed
Start date
January 3, 2019
Completion date
December 1, 2022
Enrollment
254 (actual)
Sites
14

Conditions

As the registry lists them; a condition with its own page is linked.

liver cirrhoses